Betamethasone Valerate
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
Betamethasone Valerate: Drug Repurposing Evaluation Report
One-Sentence Summary
Betamethasone valerate is a topical corticosteroid widely used for inflammatory and pruritic dermatoses, currently marketed in Malaysia with 23 registered licences. The TxGNN model has not generated any predicted new indications for this drug at this time, and critical data gaps (DrugBank ID, mechanism of action, regulatory label details) prevent a meaningful repurposing assessment.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (licence indication text missing) |
| Predicted New Indication | None — no TxGNN predictions generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (no predictions or supporting studies) |
| Malaysia Market Status | ✓ Marketed (已上市) |
| Number of Registrations | 23 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
There is currently no TxGNN prediction to evaluate. The predicted_indications array is empty, meaning the model did not return any repurposing candidates for betamethasone valerate in this run.
Based on publicly available knowledge, betamethasone valerate is a synthetic glucocorticoid ester with potent anti-inflammatory, immunosuppressive, and antipruritic properties. It acts by binding to intracellular glucocorticoid receptors, suppressing the transcription of pro-inflammatory cytokines (e.g., IL-1, IL-6, TNF-α) and inhibiting phospholipase A₂, thereby reducing prostaglandin and leukotriene synthesis. It is predominantly used as a topical formulation for dermatological conditions such as eczema, psoriasis, and contact dermatitis.
However, the evidence pack lacks a DrugBank ID and formal MOA data ([Data Gap]), which limits the ability to computationally link this drug to novel disease targets within the TxGNN knowledge graph. Resolving the DrugBank mapping is a prerequisite for generating meaningful predictions.
Clinical Trial Evidence
Currently no predicted indication exists, therefore no clinical trial search was performed for a repurposing direction.
Currently no related clinical trials registered for a new predicted indication.
Literature Evidence
Currently no related literature available for a new predicted indication.
Malaysia Market Information
23 licences are registered; however, detailed licence information (authorisation numbers, product names, dosage forms, and approved indication text) was not available in the evidence pack.
| Authorisation Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| (data not provided) | — | — | — |
Note: The raw licence records returned empty fields. A follow-up query to the NPRA database is needed to populate this table.
Safety Considerations
Please refer to the package insert for safety information. Key warnings, contraindications, and drug–drug interaction data were not available in this evidence pack (flagged as
[Data Gap]/not_found).
Conclusion and Next Steps
Decision: Hold
Rationale: No repurposing candidates were generated by TxGNN for betamethasone valerate. Multiple blocking data gaps — including the absence of a DrugBank ID, mechanism of action, regulatory label text, and safety profile — prevent any meaningful evaluation. The drug cannot proceed through the repurposing pipeline until these foundational data elements are resolved.
To proceed, the following is needed:
- Resolve DrugBank mapping — Query DrugBank for “betamethasone valerate” (likely maps to DB00394 for betamethasone or a salt-specific entry) and update
drugbank_idin the evidence pack. - Retrieve MOA data — Once the DrugBank ID is confirmed, extract the mechanism of action, pharmacodynamics, and target information.
- Populate NPRA licence details — Re-query the NPRA database to obtain authorisation numbers, product names, dosage forms, and approved indication text for the 23 registered licences.
- Extract safety information — Download and parse the package insert (仿單) PDF to populate key warnings, contraindications, and drug interactions.
- Re-run TxGNN prediction — With the DrugBank ID and complete drug profile in place, re-execute the KG and DL prediction pipeline to determine if any repurposing candidates emerge.
Disclaimer: This report is for research purposes only and does not constitute medical advice. Any drug repurposing candidates require rigorous clinical validation before application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.